160 related articles for article (PubMed ID: 32986383)
21. AS04-adjuvanted human papillomavirus (HPV) types 16 and 18 vaccine (Cervarix®): a review of its use in the prevention of premalignant cervical lesions and cervical cancer causally related to certain oncogenic HPV types.
McKeage K; Romanowski B
Drugs; 2011 Mar; 71(4):465-88. PubMed ID: 21395359
[TBL] [Abstract][Full Text] [Related]
22. Natural history of human papillomavirus type 16 virus-like particle antibodies in young women.
Ho GY; Studentsov YY; Bierman R; Burk RD
Cancer Epidemiol Biomarkers Prev; 2004 Jan; 13(1):110-6. PubMed ID: 14744741
[TBL] [Abstract][Full Text] [Related]
23. IgG antibodies to human papillomavirus 16, 52, 58, and 6 L1 capsids: case-control study of cervical intraepithelial neoplasia in Japan.
Matsumoto K; Yoshikawa H; Yasugi T; Nakagawa S; Kawana K; Takeoka A; Yaegashi N; Iwasaka T; Kanazawa K; Taketani Y; Kanda T
J Med Virol; 2003 Mar; 69(3):441-6. PubMed ID: 12526056
[TBL] [Abstract][Full Text] [Related]
24. Human papillomavirus (HPV) and Epstein-Barr virus (EBV) cervical infections in women with normal and abnormal cytology.
Szkaradkiewicz A; Wal M; Kuch A; Pieta P
Pol J Microbiol; 2004; 53(2):95-9. PubMed ID: 15478354
[TBL] [Abstract][Full Text] [Related]
25. Understanding HLA-G driven journey from HPV infection to cancer cervix: Adding missing pieces to the jigsaw puzzle.
Aggarwal R; Sharma M; Mangat N; Suri V; Bhatia T; Kumar P; Minz R
J Reprod Immunol; 2020 Nov; 142():103205. PubMed ID: 33099242
[TBL] [Abstract][Full Text] [Related]
26. Serum and cervicovaginal IgG immune responses against α7 and α9 HPV in non-vaccinated women at risk for cervical cancer: Implication for catch-up prophylactic HPV vaccination.
Mboumba Bouassa RS; Péré H; Gubavu C; Prazuck T; Jenabian MA; Veyer D; Meye JF; Touzé A; Bélec L
PLoS One; 2020; 15(5):e0233084. PubMed ID: 32421735
[TBL] [Abstract][Full Text] [Related]
27. Cervical human papillomavirus (HPV) infection and HPV type 16 antibodies in South African women.
Marais DJ; Constant D; Allan B; Carrara H; Hoffman M; Shapiro S; Morroni C; Williamson AL
J Clin Microbiol; 2008 Feb; 46(2):732-9. PubMed ID: 18077644
[TBL] [Abstract][Full Text] [Related]
28. Characterization of Immunoglobulin A/G Responses During 3 Doses of the Human Papillomavirus-16/18 ASO4-Adjuvanted Vaccine.
Gonçalves AK; Giraldo PC; Farias KJ; Machado PR; Costa AP; de Souza LC; Crispim JC; Eleutério J; Witkin SS
Sex Transm Dis; 2016 May; 43(5):335-9. PubMed ID: 27100772
[TBL] [Abstract][Full Text] [Related]
29. IgG antibodies to HPV16, 52, 58 and 6 L1-capsids and spontaneous regression of cervical intraepithelial neoplasia.
Matsumoto K; Yasugi T; Oki A; Fujii T; Nagata C; Sekiya S; Hoshiai H; Taketani Y; Kanda T; Kawana T; Yoshikawa H
Cancer Lett; 2006 Jan; 231(2):309-13. PubMed ID: 16399232
[TBL] [Abstract][Full Text] [Related]
30. Detection of immunoglobulin IgA and IgG against human papilloma virus.
Gonçalves AK; Machado PR; de Souza LC; Costa AP; Gimenes F; Consolaro ML; Crispim JO; Eleutério J; Giraldo PC
Viral Immunol; 2014 Nov; 27(9):471-7. PubMed ID: 25191973
[TBL] [Abstract][Full Text] [Related]
31. Antibody responses to HPV16 virus-like particles in women with cervical intraepithelial neoplasia infected with a variant HPV16.
Ellis JR; Etherington I; Galloway D; Luesley D; Young LS
Lancet; 1997 Apr; 349(9058):1069-70. PubMed ID: 9107250
[No Abstract] [Full Text] [Related]
32. First-void urine as a non-invasive liquid biopsy source to detect vaccine-induced human papillomavirus antibodies originating from cervicovaginal secretions.
Van Keer S; Willhauck-Fleckenstein M; Pattyn J; Butt J; Tjalma WAA; Van Ostade X; Hens N; Van Damme P; Waterboer T; Vorsters A
J Clin Virol; 2019 Aug; 117():11-18. PubMed ID: 31129514
[TBL] [Abstract][Full Text] [Related]
33. Seroresponses to human papillomavirus types 16, 18, 31, 33, and 45 virus-like particles in South African women with cervical cancer and cervical intraepithelial neoplasia.
Marais DJ; Rose RC; Lane C; Kay P; Nevin J; Denny L; Soeters R; Dehaeck CM; Williamson AL
J Med Virol; 2000 Apr; 60(4):403-10. PubMed ID: 10686023
[TBL] [Abstract][Full Text] [Related]
34. Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial.
Wheeler CM; Castellsagué X; Garland SM; Szarewski A; Paavonen J; Naud P; Salmerón J; Chow SN; Apter D; Kitchener H; Teixeira JC; Skinner SR; Jaisamrarn U; Limson G; Romanowski B; Aoki FY; Schwarz TF; Poppe WA; Bosch FX; Harper DM; Huh W; Hardt K; Zahaf T; Descamps D; Struyf F; Dubin G; Lehtinen M;
Lancet Oncol; 2012 Jan; 13(1):100-10. PubMed ID: 22075170
[TBL] [Abstract][Full Text] [Related]
35. Serum immunoglobulin A response to human papillomavirus type 16 virus-like particles in human immunodeficiency virus (HIV)-positive and high-risk HIV-negative women.
Viscidi RP; Ahdieh-Grant L; Schneider MF; Clayman B; Massad LS; Anastos KM; Burk RD; Minkoff H; Palefsky J; Levine A; Strickler H
J Infect Dis; 2003 Dec; 188(12):1834-44. PubMed ID: 14673762
[TBL] [Abstract][Full Text] [Related]
36. Antibodies to human papillomavirus 16 and subsequent in situ or invasive cancer of the cervix.
Shah KV; Viscidi RP; Alberg AJ; Helzlsouer KJ; Comstock GW
Cancer Epidemiol Biomarkers Prev; 1997 Apr; 6(4):233-7. PubMed ID: 9107427
[TBL] [Abstract][Full Text] [Related]
37. Detection of systemic and mucosal HPV-specific IgG and IgA antibodies in adolescent girls one and two years after HPV vaccination.
Scherpenisse M; Mollers M; Schepp RM; Meijer CJ; de Melker HE; Berbers GA; van der Klis FR
Hum Vaccin Immunother; 2013 Feb; 9(2):314-21. PubMed ID: 23149693
[TBL] [Abstract][Full Text] [Related]
38. Conization for cervical intraepithelial neoplasia is followed by disappearance of human papillomavirus deoxyribonucleic acid and a decline in serum and cervical mucus antibodies against human papillomavirus antigens.
Elfgren K; Bistoletti P; Dillner L; Walboomers JM; Meijer CJ; Dillner J
Am J Obstet Gynecol; 1996 Mar; 174(3):937-42. PubMed ID: 8633673
[TBL] [Abstract][Full Text] [Related]
39. Prophylactic efficacy of a quadrivalent human papillomavirus (HPV) vaccine in women with virological evidence of HPV infection.
FUTURE II Study Group
J Infect Dis; 2007 Nov; 196(10):1438-46. PubMed ID: 18008221
[TBL] [Abstract][Full Text] [Related]
40. Polymer-based enzyme-linked immunosorbent assay using human papillomavirus type 16 (HPV16) virus-like particles detects HPV16 clade-specific serologic responses.
Studentsov YY; Ho GY; Marks MA; Bierman R; Burk RD
J Clin Microbiol; 2003 Jul; 41(7):2827-34. PubMed ID: 12843008
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
